Complex multidisciplinary intervention to improve Initial Medication Adherence to cardiovascular disease and diabetes treatments in primary care (the IMA-cRCT study): mixed-methods process evaluation protocol

Carmen Corral-Partearroyo,1,2 Alba Sánchez-Viñas,1,3 Montserrat Gil-Girbau,1,4 Maria Teresa Peñarrubia-María,1,5 Ignacio Aznar-Lou,1,6 Carmen Gallardo-González,1,5 María del Carmen Olmos-Palenzuela,7 Maria Rubio-Valera1,6

ABSTRACT

Introduction Medication non-initiation, or primary non-adherence, is a persistent public health problem that increases the risk of adverse clinical outcomes. The initial medication adherence (IMA) intervention is a complex multidisciplinary intervention to improve adherence to cardiovascular and diabetes treatments in primary care by empowering the patient and promoting informed prescriptions based on shared decision-making. This paper presents the development and implementation strategy of the IMA intervention and the process evaluation protocol embedded in a cluster randomised controlled trial (the IMA-cRCT) to understand and interpret the outcomes of the trial and comprehend the extent of implementation and fidelity, the active mechanisms of the IMA intervention and in what context the intervention is implemented and works.

Methods and analysis We present the protocol for a mixed-methods process evaluation including quantitative and qualitative methods to measure implementation and fidelity and to explore the active mechanisms and the interactions between the intervention, participants and its context. The process evaluation will be conducted in primary care centres and community pharmacies from the IMA-cRCT, and participants include healthcare professionals (general practitioners, nurses and community pharmacists) as well as patients. Quantitative data collection methods include data extraction from the intervention operative records, patient clinical records and participant feedback questionnaires, whereas qualitative data collection involves semistructured interviews, focus groups and field diaries. Quantitative and qualitative data will be analysed separately and triangulated to produce deeper insights and robust results.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This process evaluation will explain how the intervention was implemented, how different components interact and work and how they influence outcomes.
⇒ This study includes a wide range of quantitative and qualitative research methods; it is logistically challenging and time consuming. A multidisciplinary research team has been involved.
⇒ The flexible and pragmatic design will be crucial to react to changes and adapt the intervention to emerging contextual factors.
⇒ Data collection methods have been designed to adapt to the participants in what we anticipate might be an overloaded and difficult time due to the persisting COVID-19 pandemic.
⇒ There is a risk of response bias among professionals that answer questionnaires and agree to participate in the qualitative evaluation as they may have engaged more with the intervention. Additionally, patients will be recruited by professionals and this might bias their responses and the decision of the patient towards filling the prescription.

Trial registration number NCT05026775.

INTRODUCTION

Medication non-initiation, or primary non-adherence, is defined as not initiating the prescribed pharmacological treatment.1 In recent years, there has been an increase in evidence regarding non-initiation.2–5 It is subject to patients’ characteristics and motivations, the pharmacological treatment prescribed and the context,4,6,7 and for some treatments, it reaches a prevalence of 40%.3
Corral-Partearroyo C, et al. BMJ Open 2022;12:e067468.

Adherence to long-term medications has been shown to be crucial to the prevention of further complications.8 Low adherence to cardiovascular disease (CVD) and diabetes treatments worsens patients’ clinical outcomes6–12 and increases direct and indirect costs to healthcare systems,10 13 14 highlighting the need for interventions to prevent it.

In the past, some studies evaluated the effectiveness of interventions to improve non-initiation, focused mainly on CVD medications.15–20 The majority were based on patients’ reminders: two on automated messages,15 19 two on phone calls performed by professionals17 18 and one on both automated and professional’s phone calls.16 Only two of these studies reported a significant decrease in non-initiation,15 19 and most showed a high overall risk of bias. Hawthorne effect and desirability bias was high overall due to lack of blinding of participants and the characteristics of the outcome under study;15–18 20 most studies used medicine acquisition as a proxy for initiation with no further follow-up, and false-positive initiation could occur when patients know they are being observed.21 22 None of the interventions tested was described as being founded on a health behaviour change theory.

In the last decade, there has been growing interest in behavioural interventions based on shared decision-making (SDM) to improve adherence.23–26 SDM is a process whereby the professional and the patient jointly decide on a treatment or healthcare choice.27 Both share their knowledge, and the patient is invited to express their preferences and consider all options to achieve a mutual agreement.27 28 This respects patient autonomy yet offers guidance to the patient by involving them in the decision at their preferred level.27 By involving the patient in the decision process, SDM increases patients’ health literacy and satisfaction.23–26 29 However, there is not sufficient evidence for an effect of SDM-based interventions on medication adherence, and there is a lack of standardised outcomes in studies evaluating the impact of SDM interventions on adherence to pharmacological treatments.25–26 29

The non-initiation project

The non-initiation project is based on the framework for developing and evaluating complex interventions proposed by the Medical Research Council (MRC)30 31 and aims to develop and evaluate an intervention to decrease non-initiation. Figure 1 summarises the project phases.

In phase I, or the development phase, the prevalence and explanatory factors of non-initiation were explored. Overall prevalence of non-initiation in primary care (PC) in Catalonia (Spain) was found to be 18% and between 6% and 9% for treatments for CVD and diabetes.5 32 Predictors of non-initiation included patient characteristics (such as being younger), the treatment (such as cost) and the system (such as receiving the prescription from a substitute or resident general practitioner (GP)).5 32 The patients’ reasons for non-initiation were explored by carrying out qualitative research with patients and professionals.7 33 Based on the results of these studies, the Initial Medication Adherence (IMA) intervention, a complex, multidisciplinary intervention to improve initiation and adherence to CVD and diabetes treatments, was modelled. To increase the acceptability of the intervention, discussion groups were conducted with GPs, nurses, pharmacists, social workers, cardiologists, endocrinologists and internists, who made suggestions for refinement, described its limitations and anticipated barriers to its implementation.

To assess the feasibility of the IMA intervention and the evaluation design, a pilot trial with an embedded process evaluation was conducted as part of phase II, or feasibility phase (ClinicalTrials.gov, NCT05094986). Detailed methods and results of the pilot study are presented elsewhere.34 The intervention components and implementation strategies were considered feasible and acceptable. However, barriers to the engagement of professionals, training for professionals and intervention decision aids

---

**Figure 1** IMA intervention phases: development, feasibility, evaluation and implementation. cRCT, cluster randomised controlled trial; IMA, initial medication adherence; PC, primary care.
were identified. These results were used to refine the IMA intervention prior to the definitive cluster-randomised controlled trial (cRCT).

The process evaluation outlined in this paper is integrated into the IMA-cRCT, phase III or evaluation phase: a pragmatic cRCT with two parallel groups that aims to evaluate the effectiveness, cost-effectiveness and understand the impact of the IMA intervention. Detailed cRCT methods (ClinicalTrials.gov, NCT05026775) are described elsewhere. The trial is being conducted in 24 PC centres in Catalonia (May 2022—September 2023), randomised to the control (usual care) or the intervention group (the IMA intervention), as well as community pharmacies in the area covered by PC centres of the intervention group. Professionals in the intervention group were trained on the IMA intervention and will apply it to all patients receiving a new prescription for lipid-lowering medication, antihypertensive medication, antiplatelet medication and/or antidiabetic medication during the study period (7 months). The primary outcome of the trial is the rate of initiation. Secondary outcomes include other measures of adherence (implementation and persistence), clinical outcomes and cost-effectiveness.

The IMA intervention

The IMA intervention is founded on the theoretical model for non-initiation. According to this model, the decision to initiate pharmacological treatments is multifactorial, and it is influenced by the patients’ beliefs about the disease and treatment options, the existence of non-pharmacological measures, the interaction with healthcare professionals (GPs, nurses and pharmacists) and the context, cultural factors and health literacy of the patient. The model suggests that an intervention that improves health literacy, helping the patient to understand the risks of the disease and the benefits and risks of treatment options and involves the patient in the decision-making process could improve initiation and long-term adherence. The model also highlights the influence of healthcare professionals and the importance of multidisciplinary recommendations when a new pharmacological treatment is prescribed.

As illustrated by the non-initiation model, the IMA intervention is expected to work at the intrapersonal level by increasing patients’ health literacy and empowerment and the interpersonal level by promoting SDM through the interaction between the patient and healthcare professionals and supporting the standardisation of clinical practice among all the PC professionals that interact with the patient (GPs, nurses and pharmacists).

During a consultation, the GP applies the principles of SDM. They define the problem and decision at hand by providing information about the disease and treatment options and exploring the patient’s perspectives, concerns and expectations supported by decision aids. Both the GP and patient have co-responsibility to negotiate a decision before the prescription of a new CVD or diabetes pharmacological treatment is issued. When necessary, the decision is delayed to offer the patient the opportunity to reflect on it, obtain complementary information (reliable decision aids are recommended as sources of information) and/or discuss the decision with others (including nurses and pharmacists). When consulted by patients, nurses and pharmacists explore patients’ queries regarding new CVD or diabetes medication prescriptions, or those of patients considering the use of medication, and use decision aids to provide information support, standardising the message from all healthcare professionals and improving interdisciplinary collaboration. In the case that the patient changes their mind about the use of medication, nurses and pharmacists refer them back to the GP. The IMA intervention is a one-shot intervention at the time of a new prescription. The dosage, or times the intervention has been applied to the same patient, varies on the healthcare professionals (GPs, nurses and pharmacists) consulted during and after a new prescription and whether they are participating in the trial, with the minimum dose being one time (when the prescription is issued).

The logic model illustrated in figure 2 shows how the intervention would primarily influence the adequate use of treatment (primary and secondary adherence) and ultimately impact the health outcomes of the population under study, as well as influence the interdisciplinary collaboration between professionals and patient—healthcare professional interaction. The IMA intervention has three main inputs as part of the implementation strategy (figure 2). First, professional engagement increases professionals’ interest and promotes participation. PC and pharmacy stakeholders, including scientific organisations, healthcare quality agencies, official colleges, and managers and directors of PC centres were first contacted and informed. Thereafter, professionals were informed at PC centres, community pharmacies and official colleges. Second, the IMA intervention training was provided to professionals (GPs, nurses and pharmacists) in two sessions of 3 hours each. Professionals were trained together to promote standardisation and mutual understanding of each other’s role and to generate bonds. The first session covers the basics of the intervention: the evidence on non-initiation, the practical aspects of the intervention, the role of each professional and the intervention decision aids. The second session was designed by an SDM expert and focuses on SDM and communication skills. Third, the IMA intervention decision aids promote discussion of all relevant topics with the patient and SDM (increasing adherence to the intervention and standardisation of practice). Leaflets (one for each pharmacotherapeutic group) contain information on the risks of the disease, the risks and benefits of pharmacological and non-pharmacological treatments and key messages to encourage the patients to express their opinions and share their uncertainties with the professional, as well as other reliable sources of information (including other healthcare professionals and a website). The website www.iniciadores.es is divided into pathologies and...
pharmacological treatments, with extended information on the disease, treatments and additional links to other reliable websites (such as those run by the national health system). The content of the leaflets and website are reliable and are endorsed by public healthcare organisations.

The IMA intervention in the context of the COVID-19

In the case of a COVID-19 outbreak, when a new treatment is recommended during a telephone consultation, the doctor sends the leaflet through email and refers the patient to the website (where leaflets are also available). Additionally, the patient can collect the leaflet from participating pharmacies when collecting the medication. In this case, a follow-up telephone consultation (GP or nurse) is recommended a week after the prescription is issued to explore patients’ queries and concerns.

Process evaluation

Randomised controlled trials (RCTs) have been presented as the gold standard for evaluating effectiveness and efficiency of complex interventions.36 Complex interventions combine multiple components that interact with each other, involve several stakeholders and generally require a behavioural change by those that implement and receive the intervention.50 51 36 However, RCTs typically have rigid designs, tend to focus mainly on outcome effect and fail to explain how the intervention was implemented and in what context, what the active components were and for whom it worked.30 31 36 Process evaluations embedded in pragmatic RCTs are needed to understand how the intervention was delivered, how different components interact and work, how they influence the intervention’s primary and secondary outcomes and its effectiveness.37

Ultimately, some very efficient interventions can be difficult to translate into routine practice, especially when the intervention cost is high because it requires organisational and behavioural changes. Assessing the cost of implementation, costs of the strategies to put in practice and sustain an intervention, provides decision makers with relevant information when evaluating the translation of the intervention into routine clinical practice.38

Aims and objectives

This process evaluation aims to understand the implementation and mechanism of action of the IMA intervention and how the context affects them and therefore understand and explain the results of the cRCT in terms of effectiveness and cost-effectiveness, refine the IMA intervention and provide information on replicability and generalisability to other contexts.

The objectives of the study are to:

1. Assess the extent to which the IMA intervention was implemented as intended (fidelity) and understand how the IMA intervention becomes integrated into routine healthcare practice (implementation).
2. Identify and understand the active mechanisms of the IMA intervention (mechanisms of impact).
3. Understand the context where the IMA intervention is implemented and identify factors that can influence the IMA intervention’s active mechanisms (context).
4. Assess the cost of implementing the IMA intervention.

METHODS AND ANALYSIS

Study design and framework of the process evaluation

A mixed-methods process evaluation study will be undertaken, involving analysis of real-world practice evidence, data collection forms, field diaries and interviews with professionals and patients. The MRC guideline for process evaluations of complex interventions was used to guide the design of this evaluation.37 It focuses on three domains that interact with each other: (1) the implementation of the intervention; (2) the mechanisms of the intervention that affect the outcomes; and (3) the characteristics of the contexts that can influence the previous domains in the intervention group and control group.
contextual factors that could influence the outcomes of the cRCT.

Figure 3 shows the interaction between the three domains and the theoretical frameworks used to evaluate them. Implementation will be assessed through the normalisation process theory, which explains how an intervention becomes routinely integrated into everyday healthcare practice by assessing four indicators: coherence, cognitive participation, collective action and reflexive monitoring. The evaluation of the mechanisms of impact and the context of the intervention will be assessed following the recommendations of realist evaluation to explain how active mechanisms of the intervention generate an effect, for whom and under what circumstances. It takes into account the expected and unexpected consequences that may result from the activation of different hypothesised mechanisms in different contexts and end up generating different effects.

Additionally, the Stages of Implementation Completion framework will be used, and the Cost of Implementing New Strategies tool will be adapted to the IMA intervention to assess the costs of implementation when translating the IMA intervention into other settings.

The process evaluation will be conducted by the IMA-cRCT research team. This is a multidisciplinary team formed by researchers with expertise in quantitative and qualitative research and PC professionals. The main components of the intervention are not expected to be adapted during the trial, although the dynamic approach of this pragmatic evaluation gives the design the flexibility to react to changes if needed.

Setting and participants
The IMA intervention will be implemented in PC centres and community pharmacies in Catalonia (Spain). PC is the gateway to the healthcare system and where the vast majority of the prescriptions for long-term treatments are issued. Patients have an assigned GP and nurse. GPs monitor and prescribe treatments and nurses follow-up the patient. Medications are electronically prescribed, and patients can fill them only at community pharmacies where the pharmacist can check the prescription directly through the electronic prescription system. A warning appears when a new platelet aggregation inhibitors excluding heparin and insulin is going to be dispensed. Full details on the cRCT setting are provided elsewhere.

The IMA-cRCT will recruit 24 PC centres, around 300 professionals and 4000 patients. The sampling strategy of the process evaluation is conditioned by the cluster sampling design of the cRCT and is detailed below.

Intervention group
Professionals
GPs, nurses and pharmacists from all PC centres will have feedback questionnaires sent to them, but only professionals from six to eight PC centres will be recruited to participate in the qualitative research due to time restrictions. The recruitment will be based on a theoretical sampling strategy according to the type of PC centre (size and location) and taking into account predictors of non-initiation (socioeconomic level of the area, rurality and the proportion of immigrant population). Professionals from the recruited PC centres will be invited to participate in the interviews by phone calls following maximum variation sampling according to role and type of contract, years of experience in PC, sex and age, nationality and owner or not of the pharmacy.

Each PC centre will have a study coordinator, a GP or nurse. The coordinator will be the link with the research team, promoting the implementation of the intervention, coordinating the distribution of intervention materials and informing the research team of external events that may influence the correct implementation of the intervention and development of the trial.
Patients
The coordinator of the PC centres will identify patients that were prescribed a new treatment for CVD or diabetes during the study period and invite them to participate in an interview. They will be asked to follow a variation sampling strategy based on medication prescribed and treatment being initiated or not. In addition, we will follow a maximum variation criterion based on the previous aspects, educational and socioeconomic level, sex and age. Once patients agree to participate, the research team will contact them by phone calls to provide further information about the study.

Control group
The coordinator from the control group PC centres will be contacted and interviewed by phone calls to explore any external events and contextual factors that could have influenced outcomes on the usual care groups and, therefore, the results of the cRCT.

Data collection
The specific objectives and research questions, as well as the data collection method used to assess the first three domains are presented in table 1 (implementation), table 2 (mechanisms of impact) and table 3 (context). Specific quantitative and qualitative methods used to meet the process evaluation aims and objectives are described for each domain.

Implementation
Data will be collected on intervention fidelity to identify how consistent the implementation of the intervention was with the initial plan and if it required any adaptations during the trial, as well as assess the implementation into routine practice (table 1). Fidelity will be assessed through quantitative data on professional interaction and the intervention implementation plan (PC centres and professional engagement, training attendance, use of intervention tools and follow-up consultations). Adaptations will be assessed using quantitative data from professionals’ feedback questionnaires and qualitative data from the coordinator’s field diary.

Additionally, qualitative methods will be used to evaluate the implementation of the IMA intervention into routine PC centre practice. Interviews with professionals will assess the perceived need and adequacy of the IMA intervention as well as measures used to appraise it. Professionals’ feedback questionnaires will collect data on professionals’ attitudes towards the IMA intervention before and after the trial and how it is operationalised and integrated into routine practice.

Mechanisms of impact
Qualitative methods will be used to identify and understand the active mechanisms of the IMA intervention that bring about any effects and explains the intervention’s logic (table 2). Interviews with professionals and patients will explore their perspectives and experiences with the intervention, potential changes to professionals’ attitudes and interdisciplinary collaboration, changes to patients’ knowledge, behaviour and interaction with professionals and any expected or unexpected consequences.

Context
Data on the context of both the intervention and control groups will be collected (table 3). Demographic data from the PC centres will be extracted from Catalan health system records. Interviews will be carried out with professionals and patients to explore the context of the PC centre and examine in which circumstances mechanisms of impact work and therefore influence the study outcomes.

Cost of implementation
To assess the cost of implementing the intervention, all human and material resources used in each stage of the implementation process to put the IMA intervention into practice will be collected and taken into account.

Data collection methods
Quantitative methods
Monitoring data
Data will be collected from the operative records, website records and clinical records from real-world databases in the public PC system in Catalonia (System for the Development of Research in Primary Care).45 Data will be structured and descriptively summarised to assess fidelity, context and cost of implementation through:

► Professional engagement: number of PC centres and professionals that decline to participate after the information session.
► Training attendance rate.
► Intervention tools usage rate: website indicators (number of views, percentage of rebound, mean view time and depth) and number of times the leaflet was downloaded.
► Follow-up consultation rate at the PC centre after a new prescription.
► Demographic records: PC centre size and location, number of professionals, socioeconomic level of the area, rurality, average age of the population and the proportion of the immigrant population.
► Implementation costs: human resources based on time invested and professional category, and consumable materials based on units used.

Professionals’ questionnaires
Professionals will be asked to complete post-training questionnaires to evaluate the quality of the training and professionals’ understanding of SDM. Furthermore, questionnaires will be sent by email to professionals during and after the cRCT. These will provide measures about adaptation and implementation, as well as professionals’ attitudes towards the intervention and its usefulness in clinical practice.
## Qualitative methods

### Field diary

A field diary will be completed by a member of the research team. It will contain field notes from periodic calls (every 2 weeks for the first month, and monthly until the study finishes) to the PC centre coordinators. Additionally, field diaries will be completed by each PC centre coordinator. These will include data on any barriers, facilitators or thoughts concerning the organisation and operation of the PC centre or pharmacy and the intervention.

### Interviews

Individual semistructured interviews will be conducted during and after the cRCT with professionals to explore their perspectives and experiences after implementing the IMA intervention and with patients to determine their experience with the IMA intervention and SDM and its impact on their behaviour in relation to the treatment. Approximately 30–40 interviews will be carried out with professionals and 20–30 with patients to ensure representativeness. Focus groups will be conducted with...
professionals after the cRCT to understand the intervention’s impact mechanisms and explore professionals’ opinions of the IMA intervention and its integration into the PC centre and pharmacy practice. Moreover, we will explore the perceived barriers and facilitators to implementation and continuity of the intervention in PC and in particular those related to COVID-19 outbreaks. About three to four focus groups will be conducted with professionals from varying PC centres. Interviews and focus groups will be recorded, anonymised and transcribed by the research team before analysis.

Different types of data will be collected at different time points: before, during, and after the trial to account for the intervention dynamics and to comprehend how the context and the intervention adapt to one another (figure 4).

### Analysis

The analysis of process evaluation data will be performed throughout the study and at the end. Quantitative data will be analysed using descriptive statistics (ie, counts, proportions and means) and regression models using Stata V.17 to describe how the intervention was implemented overall and explore variations between PC centres and pharmacies.

Qualitative data will be analysed using the principles of framework analysis by qualitative researchers. This will help researchers to organise large amounts of data systematically and focus the analysis as a group (PC centres) and as individuals (professional and patient). Field notes (from diaries) and transcripts from the interviews will be included as narrative data. After a process of familiarisation with the data (listening to recordings and reading
field notes), the researchers will use thematic content analysis to generate a coding framework following a mixed-method approach: deductive and inductive. The coding frameworks generated by the researchers will be put in common until a final one is created and applied to all the data. Data will be organised by cases and categories and will be compared within cases (PC centres) and between cases (professionals and patients) while mapping and interpreting it. NVivo software will be used to manage the data.

**Triangulation of results**

Quantitative and qualitative data from the process evaluation will be analysed separately and then interpreted in combination. First, two researchers will combine and compare the results of both, quantitative and qualitative, analyses independently. Then, a final summary of key findings will be produced jointly by the two researchers, and if there are any unresolved disagreements, another researcher will be involved. The final summary of key findings will be presented to the rest of the research team for review and clarification. The combined interpretation of results will allow us to generate deeper insights than use of either of the methods alone.

Additionally, process and effectiveness evaluation results will be integrated. Analyses will be performed separately, and once both analyses are done, the results will be combined. Combining process and effectiveness results will facilitate better understanding and interpretation of the IMA-cRCT outcomes.

**Patient and public involvement**

Patient and public were not involved in setting the research questions and outcomes of the no-initiation project, yet they have been closely involved in the development and design of the IMA intervention and its support tools and will be informed of the results through the project website suitable for a non-specialist audience.

**ETHICS AND DISSEMINATION**

The IMA-cRCT and its integrated process evaluation were approved by the Research Ethics Committee (Comitè Etic d’Investigació amb medicaments (CEIm)) at IDIAP Jordi Gol, code CEIm 21/051P. The IMA-cRCT is a low-intensity intervention clinical trial where groups of subjects are allocated to the intervention and control groups. Informed consent from patients participating in the clinical trial will be obtained by simplified means, and it fulfils the conditions described in Regulation (EU) No 536/2014 and the Real Decreto 1090/2015. Details of how informed consent will be obtained by simplified means are described somewhere else. Participation in the process evaluation is entirely voluntary. As approved by the CEIm, all healthcare professionals participating in the process evaluation will have signed an informed consent prior to the trial commencement agreeing to have feedback questionnaires sent by mail and to take part in an interview if invited to do so towards the end of the trial. Participants participating in the process evaluation will sign an informed consent after the recruitment and prior to the beginning of interviews. All participants have the right to refuse to participate and to withdraw from the study at any time.

Findings will be disseminated through publications and conferences, as well as presentations to healthcare professionals and stakeholders from healthcare organisations in Catalonia. Full details of the dissemination strategy are outlined in the main trial protocol.

**Author affiliations**

1Health Technology Assessment in Primary Care and Mental Health (PRISMA) Research Group, Parc Sanitari Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, St Boi de Llobregat, Catalunya, Spain
2Department of Paediatrics, Obstetrics, Gynaecology and Preventive Medicine, Universitat Autònoma de Barcelona, Bellaterra, Catalunya, Spain
3Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Catalunya, Spain
4Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Barcelona, Spain
5Unitat de Suport a la Recerca Regió Metropolitana Sud, Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Catalunya, Spain
6Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Comunidad de Madrid, Spain
7Primary Care Centre Bartomeu Fabrés Anglada, Institut de Recerca Sant Joan de Déu, Barcelona, Spain

**Acknowledgements**

This work has been carried out within the framework of the PhD programme in Methodology of Biomedical Research and Public Health at the Universitat Autònoma de Barcelona.

**Contributors**

MR-V obtained financing for this study and, together with CC-P, led the design, conduct and monitoring of the process evaluation. MG-G and MTP-M supported the design of the process evaluation. All authors will have a role in collecting and analysing process evaluation data as per their field of expertise. CC-P wrote the first draft of the manuscript and AS-V, MG-G, MTP-M, CG-G, MdCO-P, IA-L and MR-V added to and approved the final manuscript.

**Funding**

This project has received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 943973). IA-L has a CIBERESP contract (CIBER in Epidemiology and Public Health, CB16/02/00322). MTP-M has the ‘16th ICS support for the promotion of group research strategies through the intensification of researchers’ (7Z22/028), from the IDIAP Jordi Gol. CG-G has the ‘17th ICS...
support for the promotion of group research strategies through the intensification of researchers’ (7221,019), from the ID4AP Jordi Gol.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iD Montserrat Gil-Girbau http://orcid.org/0000-0002-4396-6492

REFERENCES

1. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012;73:691–705.

2. Hutchins DS, Zeber JE, Roberts CS, et al. Initial medication Adherence-Review and recommendations for good practices in outcomes research: an ISPOR medication adherence and persistence special interest group report. Value Health 2015;18:890–9.

3. Lemstra M, Nwankwo C, Bird Y, et al. Primary nonadherence to chronic systemic medications: a meta-analysis. Patient Prefer Adherence 2018;12:721–31.

4. Zeber JE, Manias E, Williams AF, et al. A systematic literature review of psychosocial and behavioral factors associated with initial medication adherence: a report of the ISPOR medication adherence & persistence special interest group. Value Health 2013;16:891–900.

5. Aznar-Lou I, Fernández A, Gil-Girbau M, et al. Initial medication non-adherence: prevalence and predictive factors in a cohort of 1.6 million primary care patients. Br J Clin Pharmacol 2017;83:1328–40.

6. Menckeberg TT, Bouvy ML, Bracke M, et al. Patients’ understanding of the reasons for starting and discontinuing inhaled corticosteroids. Br J Clin Pharmacol 2008;66:255–60.

7. Gil-Girbau M, Aznar-Lou I, Peñarrubia-Maria MT, et al. Reasons for medication non-initiation: a qualitative exploration of the patients’ perspectives. Res Soc Adm Pharm 2020;16:663–72.

8. World Health Organization. Adherence to long-term therapies: evidence for action [Internet]. Geneva: World Health Organization, 2003. https://apps.who.int/iris/bitstream/handle/10665/42682/4115492.pdf?sequence=1 &isAllowed=y.

9. Bouchard M-H, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007;63:698–708.

10. Bitton A, Choudhry NK, Matlin OS, et al. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med 2013;126:357.e7–357.e27.

11. Xu T, Yu X, Ou S, et al. Adherence to antithyroid medications and stroke risk: a dose-response meta-analysis. J Am Heart Assoc 2017;6:e006371.

12. Kim Y-Y, Lee J-S, Kang H-J, et al. Effect of medication adherence on long-term all-cause mortality and hospitalization for cardiovascular disease in 65,067 newly diagnosed type 2 diabetes patients. Sci Rep 2018;8:12190.

13. Aznar-Lou I, Fernández A, Gil-Girbau M, et al. Impact of initial medication non-adherence on use of healthcare services and sick leave: a longitudinal study in a large primary care cohort in Spain. Br J Gen Pract 2017;67:e614–22.

14. Cutler RL, Fernandez-Llimos F, Frommer M, et al. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open 2018;8:e021682.

15. Derose SF, Green K, Marreet E, et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med 2013;173:38–43.

16. Fischer MA, Choudhry NK, Bykov K, et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Med Care 2014;52:1050–4.

17. Fischer MA, Jones JB, Wright E, et al. A randomized telephone intervention to reduce primary medication nonadherence. J Manag Care Spec Pharm 2015;21:124–31.

18. O’Connor PJ, Schmittdel JA, Pathak RD, et al. Randomized trial of telephone outreach to improve medication adherence and metabolic control in adults with diabetes. Diabetes Care 2014;37:3317–24.

19. Kerner DE, Knezevic EL. Use of communication tool within electronic medical record to improve primary adherence. J Am Pharm Assoc 2017;57:S270–3.

20. McCarthy ML, Ding R, Rodser NK, et al. Does providing prescription information or services improve medication adherence among patients discharged from the emergency department? A randomized controlled trial. Ann Emerg Med 2013;62:212–23.

21. Tedia YG, Bautista LE. Factors associated with false-positive self-reported adherence to antihypertensive drugs. J Hum Hypertens 2017;31:320–6.

22. Stirrat MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transit Behav Med 2015;5:470–82.

23. Saheb Kashaf M, McGill ET, Berger ZD. Shared decision-making and outcomes in type 2 diabetes: a systematic review and meta-analysis. Patient Educ Couns 2017;100:2159–71.

24. Mathijssen EGE, van den Ber JF, van den Hoogen FHJ, et al. Interventions to support shared decision making for medication therapy in long term conditions: a systematic review. Patient Educ Couns 2020;103:254–65.

25. Coronado-Vázquez V, Canet-Fajas C, Delgado-Marroquín MT, et al. Interventions to facilitate shared decision-making using decision AIDS with patients in primary health care: a systematic review. Medicine 2020;99:e21389.

26. Milky G, Thomas J. Shared decision making, satisfaction with care and medication adherence among patients with diabetes. Patient Educ Couns 2020;103:661–9.

27. Elwyn G, Edwards A, Kinnersley P, et al. Shared decision making and the concept of equipoise: the compliances of involving patients in healthcare choices. Br J Gen Pract 2000;50:892–9.

28. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med 2012;27:1361–7.

29. Légaré F, Adepkpdjou R, Stacey D, et al. Interventions for increasing the use of shared decision making by healthcare professionals. Cochrane Database Syst Rev 2018;7:CD006732.

30. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new medical Research Council guidance. BMJ 2008;337:a1655.

31. Skivington K, Mathews L, Simpson SA, et al. Framework for the development and evaluation of complex interventions: gap analysis, workshop and consultation-informed update. Health Technol Assess 2021;25:1–132.

32. Vilaplana-Carnerres C, Aznar-Lou I, Peñarrubia-Maria MT, et al. Initiation and single dispensing in cardiovascular and insulin medications: prevalence and explanatory factors. Int J Environ Res Public Health 2020;17:3358.

33. Peñarrubia-Maria MT, Gil-Girbau M, Gallardo-González MC, et al. Non-initiation of prescribed medication from a Spanish health professionals’ perspective: a qualitative exploration based on Grounded theory. Health Soc Care Community 2022;30:e213–21.

34. Corral-Partearroyo C, Sánchez-Viñas A, Gil-Girbau M, et al. Improving initial medication adherence to cardiovascular diseases and diabetes treatments in primary care: pilot trial of a complex intervention 2022.

35. Sánchez-Viñas A, Corral-Partearroyo C, Gil-Girbau M, et al. Effectiveness and cost-effectiveness of an intervention to improve Initial Medication Adherence to treatments for cardiovasculardiseases and diabetes in primary care: study protocol for a pragmatic cluster randomised controlled trial and economic model (the IMA-rcRCT study). BMJ Prim Care 2022;33:2170.

36. Oakley A, Strange V, Bonell C, et al. Process evaluation in randomised controlled trials of complex interventions. BMJ 2018;363:k4125.

37. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: medical Research Council guideline. BMJ 2015;350:h1258.

38. Eisman AB, Kilbour E, Frommer M, et al. Effectiveness of an intervention to improve medication adherence for cardiovascular diseases and diabetes in primary care: protocol for a pragmatic cluster randomised controlled trial and economic model (the IMA-cRCT study). BMC Med 2020;11:82.

39. Oakley A, Strange V, Bonell C, et al. Process evaluation in randomised controlled trials of complex interventions. BMJ 2018;363:k4125.

40. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: medical Research Council guideline. BMJ 2015;350:h1258.

41. Eismann AB, Kilbour E, Frommer M, et al. Economic evaluation in implementation science: making the business case for implementation strategies. Psychiatry Res 2020;283:112433.

42. Pawson R, Tilley N. Realist evaluation. London: SAGE, 1997: 256.

43. May C, Finch T, Mair F, et al. Understanding the implementation of complex interventions in health care: the normalization process model. BMC Health Serv Res 2007;7:149.

44. Elwyn G, Légaré F, van der Weijden T, et al. Arduous implementation: does the normalisation process model explain why it’s so difficult to
embed decision support technologies for patients in routine clinical practice. *Implement Sci* 2008;3:57.

42 May C, Finch T. Implementing, embedding, and integrating practices: an outline of normalization process theory. *Sociology* 2009;43:535–54.

43 Saldana L, Chamberlain P, Bradford WD, et al. The cost of implementing new strategies (coins): a method for mapping implementation resources using the stages of implementation completion. *Child Youth Serv Rev* 2014;39:177–82.

44 Bernal-Delgado E, García-Armesto S, Oliva J, et al. Spain: health system review. *Health Syst Transit* 2018;20:1–179.

45 SIDIAP. Sistema d’Informació per al desenvolupament de la Investigació en Atenció Prim ria [Internet]. Available: https://www.sidiap.org/

46 Russell J, Berney L, Stansfeld S, et al. The role of qualitative research in adding value to a randomised controlled trial: lessons from a pilot study of a guided e-learning intervention for managers to improve employee wellbeing and reduce sickness absence. *Trials* 2016;17:396.

47 Gale NK, Heath G, Cameron E, et al. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol* 2013;13:117.

48 Green J, Thorogood N. *Qualitative methods for health research*. London: SAGE, 2018: 440.

49 O’Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed methods studies. *BMJ* 2010;341:c4587.

50 Tonkin-Crine S, Anthierens S, Hood K, et al. Discrepancies between qualitative and quantitative evaluation of randomised controlled trial results: achieving clarity through mixed methods triangulation. *Implement Sci* 2016;11:66.

51 European Union. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance. [Internet]. Available: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32014R0536

52 Gobierno de España. Real Decreto 1090/2015, de 4 de diciembre, por el que se regulan los ensayos clínicos con medicamentos, los Comités de Ética de la Investigación con medicamentos y el Registro Español de Estudios Clínicos. [Internet]. Available: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2015-14082